herontx.com (HRTX) - Gross Profit Margin

Official company branding of Heron Therapeutics (HRTX)

Heron Therapeutics relies on government procurement of postoperative care drugs, which guarantees a predictable cash flow and high profitability. Historical gross margin demonstrates operational resilience, with the value stabilizing at 71.50. Stability is supported by in-house production in the US and growing demand for non-opioid anesthetics and oncological agents in surgery.

HRTX (herontx.com) Return on Gross Profit history from 07/04/2022 to 11/20/2026

Financial and market metric breakdowns for herontx.com (HRTX)

- market price and analyst price targets:
- cash balance and cash flow data:
Basic company analysis:Heron Therapeutics (HRTX)
Manufactured products of Heron Therapeutics

To isolate the fundamental stability of Heron Therapeutics (HRTX) from market noise, a calculation of the revenue share remaining after deducting direct production costs is utilized. By analyzing gross profit margins, an investor assesses cost management efficiency, which, for the biopharmaceutical sector, confirms the commercial potential of innovative biopolymer drug delivery systems and the long-term competitiveness of Heron Therapeutics (HRTX) in pain therapy.